Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
04 nov. 2021 16h05 HE
|
Aeterna Zentaris Inc
– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 08h00 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a...
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
04 août 2021 16h05 HE
|
Aeterna Zentaris Inc
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong...
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
29 juil. 2021 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
07 juin 2021 08h05 HE
|
Aeterna Zentaris Inc
– Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of...
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
03 juin 2021 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
17 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
10 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET CHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the...
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
06 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
–In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical...